Compare BFS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | CDNA |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 759.2M | 712.2M |
| IPO Year | 1993 | 2014 |
| Metric | BFS | CDNA |
|---|---|---|
| Price | $31.94 | $19.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 75.9K | ★ 800.2K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.14 | ★ 1.22 |
| Revenue | $282,618,000.00 | ★ $357,998,000.00 |
| Revenue This Year | $8.14 | $14.11 |
| Revenue Next Year | $5.75 | $12.00 |
| P/E Ratio | $27.99 | ★ $15.79 |
| Revenue Growth | 5.61 | ★ 14.46 |
| 52 Week Low | $29.16 | $10.96 |
| 52 Week High | $40.47 | $25.95 |
| Indicator | BFS | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.95 | 58.36 |
| Support Level | $31.42 | $19.21 |
| Resistance Level | $32.37 | $20.05 |
| Average True Range (ATR) | 0.59 | 0.88 |
| MACD | 0.11 | -0.09 |
| Stochastic Oscillator | 67.30 | 53.65 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.